No Data
No Data
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics
Cartesian Therapeutics(RNAC.US) 10% Shareholder Buys US$7.37 Million in Common Stock
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $41
Oppenheimer Maintains Cartesian Therapeutics(RNAC.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)
No Data
No Data